Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumours.
Jiao LR, Szyszko T, Al-Nahhas A, Tait P, Canelo R, Stamp G, Wasan H, Lowdell C, Philips R, Thillainayagam A, Bansi D, Rubello D, Limongelli P, Woo K, Habib NA. Jiao LR, et al. Among authors: lowdell c. Eur J Surg Oncol. 2007 Jun;33(5):597-602. doi: 10.1016/j.ejso.2007.02.021. Epub 2007 Apr 11. Eur J Surg Oncol. 2007. PMID: 17433608 Clinical Trial.
[11C]choline positron emission tomography in estrogen receptor-positive breast cancer.
Contractor KB, Kenny LM, Stebbing J, Al-Nahhas A, Palmieri C, Sinnett D, Lewis JS, Hogben K, Osman S, Shousha S, Lowdell C, Coombes RC, Aboagye EO. Contractor KB, et al. Among authors: lowdell c. Clin Cancer Res. 2009 Sep 1;15(17):5503-10. doi: 10.1158/1078-0432.CCR-09-0666. Epub 2009 Aug 25. Clin Cancer Res. 2009. PMID: 19706823
Chocolate: delicious beauty or harmful beast?
Stebbing J, Gajapathy V, Lowdell C. Stebbing J, et al. Among authors: lowdell c. Lancet Oncol. 2013 May;14(6):457-8. doi: 10.1016/S1470-2045(13)70198-0. Lancet Oncol. 2013. PMID: 23639314 No abstract available.
Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial.
Wasan H, Meade AM, Adams R, Wilson R, Pugh C, Fisher D, Sydes B, Madi A, Sizer B, Lowdell C, Middleton G, Butler R, Kaplan R, Maughan T; COIN-B investigators. Wasan H, et al. Among authors: lowdell c. Lancet Oncol. 2014 May;15(6):631-9. doi: 10.1016/S1470-2045(14)70106-8. Epub 2014 Apr 3. Lancet Oncol. 2014. PMID: 24703531 Free PMC article. Clinical Trial.
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, Kenny SL, Kay E, Hodgkinson E, Pope M, Rogers P, Wasan H, Falk S, Gollins S, Hickish T, Bessell EM, Propper D, Kennedy MJ, Kaplan R, Maughan TS; MRC COIN Trial Investigators. Adams RA, et al. Lancet Oncol. 2011 Jul;12(7):642-53. doi: 10.1016/S1470-2045(11)70102-4. Epub 2011 Jun 5. Lancet Oncol. 2011. PMID: 21641867 Free PMC article. Clinical Trial.
43 results